| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 09/12/2001 | CN1312715A Antihypersensitive combination of valsartan and calcium channel blocker |
| 09/12/2001 | CN1312076A External-use and eye ofloxacin zinc preparation |
| 09/12/2001 | CN1070868C Peptides as therapeutic agents for treatment of auto-immune diseases |
| 09/11/2001 | US6288110 Pharmaceutical compositions comprising disulfiram |
| 09/11/2001 | US6288055 Analgesic agents |
| 09/11/2001 | US6287836 Histidine kinase from Streptococcus pneumoniae and compositions therecontaining |
| 09/11/2001 | US6287786 Nucleic acid molecules encoding a new mammalian protein and to the use of these molecules in the characterization, diagnosis, and treatment of conditions such as disorders associated with cell proliferation, lipid metabolism and transport. |
| 09/11/2001 | CA2230936C 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists |
| 09/07/2001 | WO2001064949A2 Diagnostics and therapeutics for glaucoma |
| 09/07/2001 | WO2001064870A2 Mutated cyclin g1 protein |
| 09/07/2001 | WO2001064754A1 Gene recombinant antibody and its fragment |
| 09/07/2001 | WO2001064750A2 Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis |
| 09/07/2001 | WO2001064749A2 Method for preparing anti-mif antibodies |
| 09/07/2001 | WO2001064679A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| 09/07/2001 | WO2001064669A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | WO2001064668A2 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 09/07/2001 | WO2001064666A1 Oxygen-containing heterocyclic compounds |
| 09/07/2001 | WO2001064661A1 Antioxidants |
| 09/07/2001 | WO2001064655A1 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/07/2001 | WO2001064653A1 Pyrimidine compounds |
| 09/07/2001 | WO2001064639A2 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | WO2001064637A1 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses |
| 09/07/2001 | WO2001064634A1 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof |
| 09/07/2001 | WO2001064633A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | WO2001064632A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | WO2001064280A1 Method and apparatus for transcutaneous infusion of carbon dioxide for local relief of pain and other ailments |
| 09/07/2001 | WO2001064250A1 Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof |
| 09/07/2001 | WO2001064228A1 Method for producing a bioactive substance from blood serum |
| 09/07/2001 | WO2001064220A1 Use of trimetazidine to inhibit acyl-coa acetyl transferase |
| 09/07/2001 | WO2001064165A2 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064163A2 An improved herbal composition having antiallergic properties and a process for the preparation thereof |
| 09/07/2001 | WO2001016135A3 Reverse-turn mimetics and methods relating thereto |
| 09/07/2001 | WO2001013901A3 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| 09/07/2001 | WO2000075107A3 Bradykinin receptor antagonists |
| 09/07/2001 | CA2401775A1 Diagnostics and therapeutics for glaucoma |
| 09/07/2001 | CA2401697A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | CA2401667A1 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | CA2401621A1 Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis |
| 09/07/2001 | CA2401489A1 Oxygen-containing heterocyclic compounds |
| 09/07/2001 | CA2400375A1 Method and apparatus for transcutaneous infusion of carbon dioxide for local relief of pain and other ailments |
| 09/07/2001 | CA2400138A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | CA2400116A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | CA2399704A1 Pyrimidine compounds |
| 09/07/2001 | CA2398685A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/06/2001 | US20010020021 Metalloprotease inhibitor |
| 09/06/2001 | US20010020013 Polymerase inhibitors |
| 09/05/2001 | EP1130123A2 Diagnostic method |
| 09/05/2001 | EP1129718A2 Therapeutic uses of bactericidal/permeability increasing protein products |
| 09/05/2001 | EP1129711A2 Pinolenic acid against diabetes |
| 09/05/2001 | EP1129110A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 09/05/2001 | EP1129086A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 09/05/2001 | EP1129075A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors |
| 09/05/2001 | EP1129074A2 Antrhranilic acid amides and the use thereof as medicaments |
| 09/05/2001 | EP1128830A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
| 09/05/2001 | EP1128826A1 Chromone enteric release formulation |
| 09/05/2001 | EP1128820A1 Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 09/05/2001 | EP0832061B1 Benzamide derivatives and their use as vasopressin antagonists |
| 09/05/2001 | CN1311796A Peptide antiangiogenic drugs |
| 09/05/2001 | CN1311767A Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
| 09/05/2001 | CN1311684A Propylactic treatments of neovascularisation in macular degeneration |
| 09/05/2001 | CN1311680A Pyrrolo [2,3d] pyrimidine compositions and their use |
| 09/05/2001 | CN1311678A Substituted tricyclic pyrazole derivatives with protein kinase activity |
| 09/05/2001 | CN1311674A Antioxidant, antiproliferous compositions, comprising a carnitine and a cerotenoid |
| 09/05/2001 | CN1311670A Cholinergic agents in the treatment of presbyopia |
| 09/05/2001 | CN1070492C Tetracylic derivatives, process for prepn. of same and use |
| 09/04/2001 | US6284804 Intended for application to the eye, ear or nose |
| 09/04/2001 | US6284774 4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists |
| 09/04/2001 | US6284749 Mixture of fungicide with chelate compound |
| 09/04/2001 | US6284515 Signal recognition particle polypeptides and polynucleotides |
| 09/04/2001 | US6284477 Diagnostic method of use of OMP26 antigen from Haemophilus influenzae |
| 08/30/2001 | WO2001062923A2 Transporters and ion channels |
| 08/30/2001 | WO2001062905A2 Integrin antagonists |
| 08/30/2001 | WO2001062800A1 Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| 08/30/2001 | WO2001062775A2 Novel antiarrhythmic peptides |
| 08/30/2001 | WO2001062757A1 Novel compounds |
| 08/30/2001 | WO2001062756A1 Pyridinylimidazoles |
| 08/30/2001 | WO2001062750A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 08/30/2001 | WO2001062742A1 Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| 08/30/2001 | WO2001062733A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | WO2001062729A1 Novel compounds |
| 08/30/2001 | WO2001062728A1 Novel compounds |
| 08/30/2001 | WO2001062726A2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 08/30/2001 | WO2001062725A2 Methods and compositions for inhibiting angiogenesis |
| 08/30/2001 | WO2001062721A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062714A1 Novel phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062706A1 Aminoadamantane derivatives as therapeutic agents |
| 08/30/2001 | WO2001062705A2 Aminoalcohol derivatives |
| 08/30/2001 | WO2001062293A1 Preventive or therapeutic drugs for various eosinophilia-related diseases containing chymase inhibitors as the active ingredient |
| 08/30/2001 | WO2001062276A1 A stable composition comprising epidermal growth factor as an active ingredient |
| 08/30/2001 | WO2001062252A1 Tyrosine kinase inhibitors |
| 08/30/2001 | WO2001062251A1 Tyrosine kinase inhibitors |
| 08/30/2001 | WO2001062250A1 Thiazolium compounds and treatments of disorders associated with protein aging |
| 08/30/2001 | WO2001012606A3 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 08/30/2001 | WO2001012195A3 Use of morphine derivatives as medicaments for the treatment of neuropathic problems |
| 08/30/2001 | WO2001009350A3 Genetically engineered bleb vaccine |
| 08/30/2001 | WO2000040597A9 Method and composition for angiogenesis inhibition |
| 08/30/2001 | CA2401113A1 Transporters and ion channels |
| 08/30/2001 | CA2401096A1 Methods and compositions for inhibiting angiogenesis |
| 08/30/2001 | CA2401036A1 Pyridinylimidazoles |
| 08/30/2001 | CA2401013A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |